🇺🇸 FDA
Pipeline program

VANCOMYCIN , MaaT013

MPOH14

Phase 2 small_molecule active

Quick answer

VANCOMYCIN , MaaT013 for Gastrointestinal Acute Graft-versus-Host Disease (GI-aGvHD) is a Phase 2 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
Pharma Mar S.A.
Indication
Gastrointestinal Acute Graft-versus-Host Disease (GI-aGvHD)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials